Valbiotis SA (FR:ALVAL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Valbiotis SA regains full control over TOTUM•63, a plant-based dietary supplement for prediabetes and early type 2 diabetes management, after terminating its agreement with Nestlé Health Science. With the recapture of all related intellectual property and a strong cash position of €25 million, Valbiotis is preparing for the direct launch of TOTUM•63 in France by H1 2025 and seeks new international partnerships.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.